Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

patient's breathing cycle, which can be optimized for each therapy based on desired delivery. It is designed to dispense drug in an efficient and consistent manner to minimize dose-to-dose differences in and between patients. The inhaler is convenient and easy to use, and contains a dose counter that can lock out after a maximum number of doses.

About Asthma and COPD

Asthma is a chronic respiratory disorder that is characterized by inflammation and narrowing of the airways, leading to limitation or obstruction of airflow and resulting in symptoms such as episodes of wheezing, chest tightness, breathlessness and coughing. Asthma is a variable condition that can change both daily and seasonally. The Centers for Disease Control estimates there are 23 million Americans diagnosed with asthma. Despite a variety of treatments available in the United States, asthma is still poorly controlled and many patients require daily maintenance treatment with combination therapy.

Chronic obstructive pulmonary disease refers to several diseases, including chronic bronchitis and emphysema, which cause airflow obstruction and interfere with normal breathing. According to the National Heart Lung and Blood Institute, more than 12 million people in the United States have been diagnosed with COPD and another 12 million likely have the illness but do not know it. COPD is one of the leading causes of death and disability in the United States and is caused in many cases by heavy cigarette smoking in earlier life.

According to Datamonitor, a leading market research company, the potential market for asthma and COPD was estimated at approximately $19 billion in 2006, with expected growth to approximately $30 billion by 2015.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medic
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , June 26, 2010 Amylin Pharmaceuticals, ... Company (NYSE: LLY ) today announced results ... with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) ... the pancreas that produce insulin.) Three years of BYETTA ...
... ORLANDO, Fla. , June 26, 2010 ... Lilly and Company (NYSE: LLY ) and ... of an analysis of pooled safety data from three ... BYDUREON™ (exenatide extended-release for injectable suspension), dosed once weekly, ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 2BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 3BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 4BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 5BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 6BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 7BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 9
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting ... Top10BestSEOHosting.com is here to announce that JustHost, Bluehost ... in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Dec. 19 House Republican Whip,Roy Blunt (Mo.) issued ... funding under the State Children,s Health Insurance,Program (SCHIP) through ... days of the first session of the 110th,Congress, the ... for months - a proposal to extend the current ...
... IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced today ... Conference. Jonathan W. Ayers, Chairman,President and CEO, is scheduled ... 7, 2008 at 8:00 a.m. (PT), at the Westin ... live audio webcast of,the presentation through a link on ...
... Stronger National,Measures, Urges America,s Health Insurance Plan Proposal ... The National Patient,Advocate Foundation (NPAF) -- a national, ... to health care through state and,federal public policy ... today in its Individual Market Guarantee Access,Proposal that ...
... introduce NutreStore(TM) in spring 2008, TORRANCE, ... a,Torrance, California based pharmaceutical company, announced today ... agreement with Cato BioVentures of,Research Triangle Park, ... brand L-Glutamine. Under this agreement, Emmaus will,commercialize ...
... happiness and sadness. Although lost opportunities and mistaken expectations ... experiences may impact personality development and overall happiness. A ... the University of Missouri, indicates that individuals who take ... more likely to mature and achieve a potentially more ...
... in tumor-suppressing gene could point to lymph node involvement, ... Supposedly "innocent" cells in the area surrounding cancerous tumors ... can predict whether or not the cancer spreads to ... of alterations in the tumor-suppressing p53 gene in the ...
Cached Medicine News:Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 2Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 3Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:What's the rush? Taking time to acknowledge loss is not that bad 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 3
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: